Fresenius And Formycon File Ustekinumab In US

Firms Submit BLA For FYB202 Stelara Biosimilar To FDA; Launch Anticipated In April 2025

 
• By David Wallace
  
Sign outside of FDA's headquarters in White Oak, MD
Fresenius Kabi and Formycon have submitted their filing to the FDA • Source: Alamy
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products